NEOP/NAVB Analysis - Spec. Buy - Blogs - Investor Stemcell Forum
Username or Email Address
Do you already have an account?
Forgot your password?
  • Log in or Sign up

    Welcome to InvestorStemCell
    Be a part of the Future of Medicine and join the InvestorStemCell Community! InvestorStemCell is the world's only community dedicated to Regenerative Medicine. Get started by signing up!
    View RSS Feed

    DonV

    NEOP/NAVB Analysis - Spec. Buy

    Rate this Entry
    by , 03-03-2012 at 06:04 PM (18013 Views)
    NEOP/NAVB Analysis (Navidea is focused on diagnostic and radiopharmaceutical imaging agents)

    As I'm out of ACTC for a bit, I am reviewing some of my favorite
    stocks on my watch list and decided to focus on my 2nd favorite stock
    which Iím not currently in at the moment. Here goes for my first full
    analysis of NAVB/NEOP.

    Core Summaries:
    Company first opened up business and became an initial public offering
    around 1992. Their first money maker was Neo2000 Gamma Detection
    System (GDS) which was their main revenue for a long time. For awhile,
    the company main focus was to create technology to detect early stages
    of various cancers which turned them into a world leader in gamma
    detection technology.

    While the GDS helped obtain them revenue, the company worked on
    another type of early detection called Lymphoseek Radiopharmaceutical
    which is patented. The system is an upgraded and redesigned GDS which
    was successful for them initially. However, instead of relying solely
    on Gamma and devices to detect certain cancers at early stages they
    combined it using new research by oncology surgeons of following the
    lymph node system as targeting cancer cells. Lymphoseek at the moment
    are past Phase I, II and just recently completed Phase III in 2011.
    They are also way ahead by filing for a NDA back in August 2011 and
    should be approved/rejected somewhere around April/June 2012.

    Check out the detailed information of the actual program and why using
    lymph makes sense with a higher accuracy of finding the cancer cells.
    The most important reason why I want to get back in is they have meet
    and exceeded the primary end points for Phase III Trials. One of the
    biggest reason why Iím interested is instead of big pharm. always
    trying to cure or treat late stages cancer or other diseases, NEOP/
    NAVB are trying to develop ways to target them early on in the stages.

    Competitors:
    Biggest competitor to the Lymphoseek system is a couple year old
    decade vital blue dyes which also uses the lymph node system. NEOP/
    NAVB used this as a comparison since the blue dye is designated as the
    "Truth Standard" Comparator. The company pretty demolishes the so
    called truth standard with the following results:
    Lymphoseekģ (Tilmanocept) Meets All Endpoints in NEO3-09 Phase 3 Study | Business Wire

    Partnership:
    The company has signed with one of the largest health care distributer
    Cardinal Health which they gave up a good portion of the market to use
    Cardinal Health. Under the terms of the agreement Neoprobe and
    Cardinal Health will receive a 50%/50% revenue split and Neoprobe will
    receive up to $3M upon the achievement of certain sales milestones by
    Cardinal Health.
    Healthcare Sales & Marketing Network: Neoprobe and Cardinal Health Sign Distribution Agreement for Lymphoseek (HSMN NewsFeed)

    In an interesting turn of events to improve their balance sheet and
    obtain more cash reserves, they sold their only product line bringing
    in their revenue to Devicor Medical Products for $30 Million in Cash
    and up to $20 Million in Roylaties. I was very surprised by this move,
    but at the same time gave me the feel of confidence by the company
    they were not even one bit worried about FDA rejecting their
    application since they met all primary end points and far exceeded
    anyone expectation in the Phase III Trials.
    Neoprobe to sell gamma detection business | BioTuesday


    The Bad:
    For the past year, the company has been a perfect target for Shorts.
    One of the leading Shorters was Martin Shkreli which in my opinion
    played his cards perfectly. He single handedly destroyed the PPS with
    his multiple articles and even submitted a civilian application to the
    FDA to not accept NEOP market application (which later got approved to
    be review). But, the damage was done and the stock PPS drop nearly to
    a half. Later on he closed his short and moved on to his next target.
    Healthcare Sales & Marketing Network: Neoprobe and Cardinal Health Sign Distribution Agreement for Lymphoseek (HSMN NewsFeed)

    The Short Case for Neoprobe: Skeptical of Its Primary Asset's Success - Seeking Alpha

    Neoprobe: Why I'm Closing My Short Position - Seeking Alpha

    Speculation Factors:
    They are currently in the stage of waiting for approval/rejection of
    their Lymphoseek System which if approved they will IMO destroy the
    blue dye currently being used and be the gold standard for every
    hospital. As all risks in the healthcare world, they can be rejected
    will ultimately destroy their only possible money maker.

    They have a potential billion dollars market target using their Rig
    Scan program which was killed then recently started up again. It is
    still years away from the market, but this could ultimately make this
    company a big hit.

    Conclusion:
    I was in this company a year ago and got in days before Martin hit
    NEOP hard with his short tactics which destroyed the PPS. After the
    shorts left and NEOP changed their company branding to NAVB then
    completely refocus on the Lymphoseek to be approved and bringing up
    RIGScan Iím pretty confident they will be successful. Add that with
    the potential date of being approved by June 2012, Iím seeking to open
    a considerable amount of position in the late February/early March
    deadline. If approved, Lymphoseek will be targeting a potential $450
    million dollars market as it includes Breast, Head & Neck Squamous,
    Melanoma, Colon, and Prostate Cancers.

    Old Report, but most resourceful: [url]http://www.tripointglobalresearch.co...ort_092210.pdf[/url]
    Good resources on the other programs
    [url]http://lifetechcapital.com/ltc/wp-co...n-03-25-11.pdf[/url]
    [url]http://lifetechcapital.com/ltc/wp-co...e-04-01-11.pdf[/url]
    Categories
    Uncategorized

    Comments

    1. LutfiyahGroup's Avatar
      Good luck for your new investment but NAVB not interested.
      sticking to my NASDAQ:ACTC lol